This study was designed to elucidate hemostatic and genetic characteristics associated with thrombosis of the left atrial appendage (LAA) in patients with chronic atrial fibrillation (AF). It included 91 patients (mean age 62 ± 7.6 years) with coronary heart disease (CHD) and chronic AF. Group I was comprised of 63 patients without LAA thrombosis, group 2 contained 28 patients with LAA thrombosis diagnosed by transesophageal echocardiography. The following parameters were measured: soluble fibrin monomeric complex, fibrinogen, antithrombin, thrombin-activated fibrinolysis inhibitor levels and polymorphism of YP29, VKORC1, PAI-1 genes. Multifactor regression analysis revealed significant association of LAA thrombosis with thrombin-activated fibrinolysis inhibitor level in excess of 245%, the presence of CC genotype of the VKORC1 gene and 4G allele of the PAl-1 gene.
Download full-text PDF |
Source |
---|
Sci Rep
December 2024
Department of Radiology, Yantai Yuhuangding Hospital, Affiliated Hospital of Qingdao University, Yantai, 264000, Shandong, China.
To investigate whether we can rule out the left atrial appendage (LAA) thrombus in patients with atrial fibrillation (AF) using different scanning protocol by Cardiovascular Computed Tomography (CCT). We retrospectively reviewed the CCT images of 138 patients with AF to assess LAA thrombus. Patients with no thrombosis diagnosed by preoperative CCT should be confirmed using intraoperative findings as the reference standard.
View Article and Find Full Text PDFInt J Cardiol
February 2025
Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China. Electronic address:
Background: The morphology of the left atrium (LA) and left atrial appendage (LAA) is associated with LAA thrombus formation (LAAT) in patients with atrial fibrillation (AF). Statistical shape modeling (SSM) could be a comprehensive and objective method for evaluating LA/LAA shape, thereby improving LAAT risk assessment.
Methods And Results: In this individual-matched case-control study, 110 pairs of AF patients with or without LAAT were compared.
BMC Cardiovasc Disord
November 2024
Department of Internal Medicine I, Cardiology, Angiology, Intensive Medical Care, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Background: In symptomatic high-risk patients with severe mitral valve regurgitation (MR), who are not eligible for surgery, Transcatheter edge-to-edge repair (TEER) or transcatheter mitral valve replacement (TMVR) may be an option, especially when surgical mitral valve repair by annuloplasty has been performed earlier. After TMVR, the appropriate anticoagulation regimen is still matter of debate.
Case Presentation: We here report on a 78-year-old frail lady with heart failure and atrial fibrillation who underwent surgical reconstruction of the mitral valve nine years ago.
Heart Rhythm
November 2024
Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
Background: Patients with atrial fibrillation and malignant left atrial appendage (LAA) may benefit from LAA closure (LAAC); however, evidence is limited.
Objective: The purpose of this study was to determine management strategies and clinical outcomes in patients with atrial fibrillation and malignant LAA.
Methods: Malignant LAA was defined as a history of ischemic stroke and/or evidence of LAA thrombus despite continuous oral anticoagulation (OAC) therapy (continuous for ≥3 weeks).
J Clin Med
October 2024
Department of Biomedical, Surgical and Dental Sciences, Università di Milano, 20122 Milan, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!